Yiming Zhang

Yiming Zhang

Auto-generated profile, based on publicly available information

Yiming Zhang

Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2024 in Cell Metabolism
Verified
Journal Article
Open access
YZYiming Zhang
Yiming Zhang
CHCassandra B. Higgins
Cassandra B. Higgins
STStefani Tica
Stefani Tica
JAJoshua A. Adams
Joshua A. Adams
JSJiameng Sun
Jiameng Sun
BDBrian J. DeBosch
Brian J. DeBosch
Urea cycle impairment and its relationship to obesity and inflammation remained elusive, partly due to the dramatic clinical presentation of classical urea cycle defects. We generated mice with hepatocyte-specific arginase 2 deletion (Arg2LKO) and revealed a mild compensated urea cycle defect. Stable isotope tracing and respirometry revealed hepatocyte urea and TCA cycle flux defects, impaired mitochondrial oxidative metabolism, and glutamine anaplerosis despite normal energy and glucose homeostasis during early adulthood. Yet during middle adulthood, chow- and diet-induced obese Arg2LKO mice develop exaggerated glucose and lipid derangements, which are reversible by replacing the TCA cycle oxidative substrate nicotinamide adenine dinucleotide. Moreover, serum-based hallmarks of urea, TCA cycle, and mitochondrial derangements predict incident fibroinflammatory liver disease in 106,606 patients nearly a decade in advance. The data reveal hierarchical urea-TCA cycle control via ARG2 to drive oxidative metabolism. Moreover, perturbations in this circuit may causally link urea cycle compromise to fibroinflammatory liver disease.

1 July 2019 in Current Opinion in Clinical Nutrition and Metabolic Care
Verified
Journal Article
Closed access
YZYiming Zhang
Yiming Zhang
BDBrian J. DeBosch
Brian J. DeBosch
Purpose of review Trehalose is a disaccharide with manifold industrial, commercial and biomedical uses. In the decade following its initial definition as an autophagy-inducing agent, significant advances have been realized in regard to the applicable clinical and preclinical contexts in which trehalose can be deployed. Moreover, the mechanisms by which trehalose exerts its metabolic effects are only beginning to gain clarity. In this review, we will highlight the most recent advances regarding the effectiveness and mechanisms of trehalose actions in metabolic disease, and discuss barriers and opportunities for this class of compounds to advance as a clinical therapeutic. Recent findings Trehalose reduced cardiometabolic disease burden in diet-induced and genetic models of atherosclerosis, dyslipidemia, hepatic steatosis and insulin tolerance and glucose tolerance. The mechanism by which these effects occurred were pleiotropic, and involved activation of fasting-like processes, including autophagic flux and transcription factor EB. These mechanisms depend heavily on route of administration and disease-specific context. Host and microbial trehalase activity is likely to influence trehalose efficacy in a tissue-dependent manner. Summary Trehalose and its analogues are promising cardiometabolic therapeutic agents with pleiotropic effects across tissue types. It is likely that we are only beginning to uncover the broad efficacy and complex mechanisms by which these compounds modulate host metabolism.

28 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
CHCassandra B. Higgins
Cassandra B. Higgins
AMAllyson L. Mayer
Allyson L. Mayer
YZYiming Zhang
Yiming Zhang
MFMichael Franczyk
Michael Franczyk
SBSamuel Ballentine
Samuel Ballentine
BDBrian J. DeBosch
Brian J. DeBosch
Calorie restriction abates aging and cardiometabolic disease by activating metabolic signaling pathways, including nicotinamide adenine dinucleotide (NAD+) biosynthesis and salvage. Nicotinamide phosphoribosyltransferase (NAMPT) is rate-limiting in NAD+ salvage, yet hepatocyte NAMPT actions during fasting and metabolic duress remain unclear. We demonstrate that hepatocyte NAMPT is upregulated in fasting mice, and in isolated hepatocytes subjected to nutrient withdrawal. Mice lacking hepatocyte NAMPT exhibit defective FGF21 activation and thermal regulation during fasting, and are sensitized to diet-induced glucose intolerance. Hepatocyte NAMPT overexpression induced FGF21 and adipose browning, improved glucose homeostasis, and attenuated dyslipidemia in obese mice. Hepatocyte SIRT1 deletion reversed hepatocyte NAMPT effects on dark-cycle thermogenesis, and hepatic FGF21 expression, but SIRT1 was dispensable for NAMPT insulin-sensitizing, anti-dyslipidemic, and light-cycle thermogenic effects. Hepatocyte NAMPT thus conveys key aspects of the fasting response, which selectively dissociate through hepatocyte SIRT1. Modulating hepatocyte NAD+ is thus a potential mechanism through which to attenuate fasting-responsive disease.

8 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
YZYiming Zhang
Yiming Zhang
CHCassandra B. Higgins
Cassandra B. Higgins
HFHannah M. Fortune
Hannah M. Fortune
PCPhillip Chen
Phillip Chen
ASAlicyn I. Stothard
Alicyn I. Stothard
BDBrian J. DeBosch
Brian J. DeBosch
Caloric restriction and intermittent fasting are emerging therapeutic strategies against obesity, insulin resistance and their complications. However, the effectors that drive this response are not completely defined. Here we identify arginase 2 (Arg2) as a fasting-induced hepatocyte factor that protects against hepatic and peripheral fat accumulation, hepatic inflammatory responses, and insulin and glucose intolerance in obese murine models. Arg2 is upregulated in fasting conditions and upon treatment with the hepatocyte glucose transporter inhibitor trehalose. Hepatocyte-specific Arg2 overexpression enhances basal thermogenesis, and protects from weight gain, insulin resistance, glucose intolerance, hepatic steatosis and hepatic inflammation in diabetic mouse models. Arg2 suppresses expression of the regulator of G-protein signalling (RGS) 16, and genetic RGS16 reconstitution reverses the effects of Arg2 overexpression. We conclude that hepatocyte Arg2 is a critical effector of the hepatic glucose fasting response and define a therapeutic target to mitigate the complications of obesity and non-alcoholic fatty liver disease.

1 April 2020 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
YZYiming Zhang
Yiming Zhang
NSNurmohammad Shaikh
Nurmohammad Shaikh
JFJeremie L. Ferey
Jeremie L. Ferey
UWUmesh D. Wankhade
Umesh D. Wankhade
SCSree V. Chintapalli
Sree V. Chintapalli
BDBrian J. DeBosch
Brian J. DeBosch

19 August 2014 in SpringerPlus
Verified
Journal Article
Open access
PDF file
MCMingjie Chen
Mingjie Chen
RRR. Shyama Prasad Rao
R. Shyama Prasad Rao
YZYiming Zhang
Yiming Zhang
CZCathy Xiaoyan Zhong
Cathy Xiaoyan Zhong
JTJay J. Thelen
Jay J. Thelen
The goal of metabolomics data pre-processing is to eliminate systematic variation, such that biologically-related metabolite signatures are detected by statistical pattern recognition. Although several methods have been developed to tackle the issue of batch-to-batch variation, each method has its advantages and disadvantages. In this study, we used a reference sample as a normalization standard for test samples within the same batch, and each metabolite value is expressed as a ratio relative to its counterpart in the reference sample. We then applied this approach to a large multi-batch data set to facilitate intra- and inter-batch data integration. Our results demonstrate that normalization to a single reference standard has the potential to minimize batch-to-batch data variation across a large, multi-batch data set.